Shots:
- Orca Bio reported positive P-I study data for Orca-Q, showing rapid neutrophil recovery, low acute/chronic GvHD, reduced infections, and low non-relapse mortality, including in patients treated without any GvHD prophylaxis
- Patients receiving Orca-Q with tacrolimus (Arm A, n=18) vs. without immunosuppression (Arm C, n=26) showed comparable survival and GvHD outcomes, with faster neutrophil engraftment (15 vs. 11 days), similar 1yr OS (94% vs. 87%), GRFS (77% vs. 79%), RFS (88% vs. 87%), and lower NRM (6% vs. 0%) and mod-sev chronic GvHD at Day 180 (12% vs. 0%) in the no-tac group, which also demonstrated better immune recovery and fewer Grade 2+ infections (33% vs. 17%)
- In two P-I studies in high-risk r/r B-ALL, OrCAR-T (Orca-T + allogeneic CD19/CD22 CAR-T; n=16) demonstrated markedly superior outcomes vs. autologous CD19/22 CAR-T (n=17), with 18mons. PFS 100% vs. 38.5 and OS of 100% vs. 77% in OrCAR-T and autologous CD19/22 CAR-T cohorts, respectively
Ref: Orca Bio | Image: Orca Bio | Press release
Related News: Nurix Therapeutics Presents New Data from P-I of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL at ASH’25
PharmaShots, your go-to media platform for customized news across multiple therapeutic areas. For more information, reach us at connect@pharmashots.com
